Literature DB >> 1795499

Ocular pseudo-myasthenic reaction induced by interferon in an AIDS patient.

R R Riedel1, A Schmitt, A Hartmann.   

Abstract

A 32-year-old, HIV-positive homosexual with Kaposi's sarcoma was given subcutaneous interferon-A (IFN) for two- and a-half months. The patient complained of ocular symptoms (ptosis of the left eyelid and intermittent diplopia) after the application of IFN-A. These symptoms persisted for the period of treatment and subsided after therapy was stopped. However after IFN-A was resumed, ptosis and diplopia recurred. Intensive serological and neurological diagnostic investigations failed to present any reason for these ocular symptoms. From data and the clinical appearance we suppose that in this case the patient suffered a pseudo-myasthenic reaction to IFN-A.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1795499     DOI: 10.1007/BF01798543

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  4 in total

Review 1.  Central nervous system toxicity of interferons and other cytokines.

Authors:  V Bocci
Journal:  J Biol Regul Homeost Agents       Date:  1988 Jul-Sep       Impact factor: 1.711

Review 2.  Interferons.

Authors:  F R Balkwill
Journal:  Lancet       Date:  1989-05-13       Impact factor: 79.321

3.  Neurotoxicity of interferon.

Authors:  K Mattson; A Niiranen; M Iivanainen; M Färkkilä; L Bergström; L R Holsti; H L Kauppinen; K Cantell
Journal:  Cancer Treat Rep       Date:  1983-10

4.  Safety and tolerance of recombinant interferon alfa-2a (Roferon-A) in cancer patients.

Authors:  G J Jones; L M Itri
Journal:  Cancer       Date:  1986-04-15       Impact factor: 6.860

  4 in total
  2 in total

1.  Myasthenia gravis in a patient with chronic active hepatitis C during interferon-alpha treatment.

Authors:  G Piccolo; D Franciotta; M Versino; E Alfonsi; M Lombardi; G Poma
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-03       Impact factor: 10.154

2.  Myasthenia gravis developing in an HIV-negative patient with Kaposi's sarcoma.

Authors:  Vittorio Mantero; Maria Mascolo; Monica Bandettini di Poggio; Claudia Caponnetto; Matteo Pardini
Journal:  Neurol Sci       Date:  2012-09-26       Impact factor: 3.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.